证券代码：300676 证券简称：华大基因 公告编号：2026-012 深圳华大基因股份有限公司 1、会议召开的日期、时间： （1）现场会议召开时间：2026年2月12日（星期四）14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2026年2月12日9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网 投票系统投票的具体时间为2026年2月12日9:15至15:00的任意时间。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要提示： 1、本次股东会召开期间不存在增加、否决或变更议案情形； 2、本次股东会未涉及变更前次股东会决议的情形。 一、会议召开情况 2026 年第一次临时股东会决议公告 2、会议召开地点：广东省深圳市盐田区梅沙街道云华路9号华大时空中心 C 区国际会议中心419会议室 1、股东出席的总体情况 通过现场和网络投票的股东400人，代表股份163,057,432股，占公司有表决 权股份总数的38.9794％。其中：通过现场投票的股东8人，代表股份158,487,288 股，占 ...

Core Insights - The article highlights the launch of the "Yantian Good Products Caravan" at the Yantian New Year Flower Market, showcasing local enterprises and innovative products, aiming to enhance visibility and consumer engagement [1][4]. Group 1: Event Overview - The "Yantian New Year Flower Market" opened on February 6, featuring a vintage caravan that serves as a platform for local businesses to showcase their products [1]. - The event is part of the "Mountain and Sea Selection: Yantian New Year Gift Market," which integrates new productive forces into the festive atmosphere [1]. Group 2: Company Highlights - Shenzhen Andofor Disinfection Technology Co., Ltd., a key participant, has been rooted in Yantian for 28 years and is recognized as a national high-tech enterprise with 19 patents in disinfection technology [1][2]. - Lei Ming Technology, known for its coffee sourced directly from Ethiopian farmers, emphasizes a modern supply chain that preserves the flavor of its products [2]. - BGI Group, a significant player in the biopharmaceutical sector, showcased its "Little Deer Essence," reflecting the warmth of biotechnology [2]. Group 3: Community and Economic Impact - The caravan initiative aims to connect local agricultural products with broader markets, facilitating interactions between Yantian and other regions, such as a partnership with the agricultural sector in Raoping [3]. - The event is designed to transform policy support into tangible consumer experiences, promoting mutual prosperity and community engagement [3]. Group 4: Consumer Experience - The market offers a diverse range of products, allowing consumers to experience local and national specialties in a single location, enhancing the shopping experience [5]. - Customers expressed satisfaction with the variety of products available, indicating a successful integration of local goods and broader market offerings [5]. Group 5: Future Prospects - The caravan is set to expand its reach in 2026, continuing to promote local enterprises and foster community connections [6].

近日，一则人事变动公告将"85后"博士侯勇推至中国基因测序龙头华大基因（300676）的台前。日前， 华大基因宣布聘任侯勇为新任总经理，这位兼具前沿科研、产业化与国际化复合背景的新帅，将带领华 大基因驶向何方，备受业界关注。 从专注单细胞组学研究的科学家，到推动国产测序仪在欧洲成功商业化的国际业务操盘手，再到如今执 掌华大基因的总经理，侯勇的履历与华大基因的战略转型高度契合。面对AI浪潮，华大基因将如何布 局？又将怎样平衡技术创新与全球化扩张？ "短期内，公司将聚焦核心业务稳增长、提效益……中期来看，我们的目标是推动公司从基因检测服务 商向生命健康智能平台跃迁，让基因检测成本进入'百元级'。"近日，履新不久的侯勇在接受《每日经 济新闻》记者专访时，清晰地描绘了公司发展蓝图。 当前，"人工智能+"已成为驱动新质生产力发展的核心引擎，AI与医疗的深度融合更是大势所趋。在侯 勇的规划中，AI与国际化将成为支撑华大基因战略转型的"双轮驱动"。一方面，公司将通过AI大模型技 术打造核心医疗体系，驱动业务升级，力求降低基因解读成本；另一方面，海外拓展将聚焦"一带一 路"与金砖国家，推行"一国一策"的深度本土化战略，打开广 ...

Core Viewpoint - The Biotech Index (970038) closed at 2196.51 points, up 0.05%, with a trading volume of 15.75 billion yuan and a turnover rate of 1.32% [1] Group 1: Index Performance - On the day, 20 stocks in the Biotech Index rose, with Furuimei leading at a 4.45% increase, while 28 stocks fell, with Aimeike leading the decline at 2.87% [1] - The net outflow of main funds from the Biotech Index constituents totaled 327 million yuan, while retail funds saw a net inflow of 162 million yuan [1] Group 2: Top Constituents - The top ten constituents of the Biotech Index include: - Mindray Medical (sz300760) with a weight of 13.73%, latest price of 190.36 yuan, and a market cap of 230.8 billion yuan [1] - Deep Technology (sz000021) with a weight of 5.05%, latest price of 28.69 yuan, and a market cap of 45.09 billion yuan [1] - Tigermed (sz300347) with a weight of 4.85%, latest price of 66.60 yuan, and a market cap of 57.34 billion yuan [1] - Other notable constituents include Changchun High-tech, Kanglong Chemical, and Yuyue Medical, all within the biotech sector [1] Group 3: Fund Flow Details - Detailed fund flow for selected stocks shows: - Kanglong Chemical (300759) had a main fund inflow of 10.6 million yuan, but retail funds saw a net outflow of 87.37 million yuan [2] - Furuimei (300049) experienced a main fund inflow of 63.48 million yuan, while retail funds had a net outflow of 64.28 million yuan [2] - Mindray Medical (300760) had a main fund inflow of 45.80 million yuan, with retail funds also experiencing a net outflow [2]

深圳华大基因股份有限公司 关于召开 2026 年第一次临时股东会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 根据《中华人民共和国公司法》和《深圳华大基因股份有限公司章程》（以下简 称《公司章程》）的有关规定，经深圳华大基因股份有限公司（以下简称公司）第四 届董事会第八次会议审议通过，公司董事会决定于2026年2月12日（星期四）召开公 司2026年第一次临时股东会。《关于召开2026年第一次临时股东会的通知》（公告编 号：2026-009）已于2026年1月28日在巨潮资讯网（http://www.cninfo.com.cn，下同） 进行了公告。本次会议将采取现场表决与网络投票相结合的方式召开，根据相关规定， 现就本次会议有关事项提示如下： 一、召开会议的基本情况 证券代码：300676 证券简称：华大基因 公告编号：2026-011 1、股东会届次：2026年第一次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号—创业 ...

人体内的免疫系统就像一支庞大而精密的"护卫队"，每一个免疫细胞都是一名独特的"士兵"，它们 各司其职又紧密配合，守护着人体健康。然而，长期以来，科学家们观察这个复杂的微观世界都像是隔 着一层"毛玻璃"——虽然知道免疫细胞种类繁多，却难以看清每个细胞的具体特征和它们之间的调控关 系。 深圳华大生命科学研究院牵头建设的基因组多维解析技术全国重点实验室联合上海交通大学医学院附属 瑞金医院、山西医科大学等多家机构的研究团队，通过对中国自然人群队列中超过1000万个外周血免疫 细胞进行系统性多组学深度解析，绘制出高分辨率人群免疫多组学图谱（CIMA）。这也是全球首个千 万级免疫细胞图谱。相关研究成果前不久发表在《科学》上。 突破免疫学研究传统视角局限 传统免疫学研究大多停留在主要细胞类型层面，这就好比只能区分免疫细胞中哪些是"陆军"，哪些 是"海军"，但对内部更精细的兵种构成知之甚少。有了CIMA，就像为研究配备了一台高清"显微镜"， 突破了以往免疫学研究视角的局限。 中国工程院院士、上海交通大学医学院附属瑞金医院院长宁光介绍："CIMA通过千万级细胞分析，系 统解析了遗传、年龄、性别等因素对免疫系统的精细影响，为人群 ...

广东年菜香飘上海，佛山年桔热销全球，湛江海鲜闪耀湘江……"广货行天下"，这场促消费行动不仅藏 着广东制造业、服务业的发展密码，更蕴含着广东农业农村发展的强劲动能。 2月7日，"广货行天下"之大V主播地市行清远专场暨粤味珍品・清远好食材年货节在清远启幕；2月6 日，"广货行天下"为东北老铁送去兴宁鸽等近百款"粤字号"农产品；还有前不久举办的粤味组团进上海 等活动……2026年"广货行天下"春季行动启动以来，越来越多"粤字号"农产品在市场上抢得先机。 今年是"十五五"开局之年，做好"三农"工作至关重要。日前发布的2026年中央一号文件明确提出，努力 把农业建成现代化大产业、使农村基本具备现代生活条件、让农民生活更加富裕美好，为推进中国式现 代化提供基础支撑。2月9日，省委农村工作会议召开，作为经济大省、农业大省的广东，如何写好"三 农"工作答卷？或许从正在火热进行的"广货行天下"春季行动这一小切口，可以窥见一斑。 筑牢发展根基 在广东深入推进"百千万工程"的背景下，"粤字号"农产品实现品牌跃迁。这背后，是近年来广东锚定建 设农业强省目标，扎实做好"土特产"文章，加快构建粮经饲统筹、农林牧渔并举、产加销贯通、农文旅 ...

Core Viewpoint - The ChiNext Medical Index (970082) closed at 3882.75 points, down 0.63%, with a trading volume of 14.157 billion yuan and a turnover rate of 2.13% on February 6 [1] Group 1: Index Performance - Among the index constituents, 22 stocks rose while 28 stocks fell, with Tigermed leading the gainers at 3.06% and Aier Eye Hospital leading the decliners at 3.82% [1] - The top ten constituents of the ChiNext Medical Index include Aier Eye Hospital (9.18% weight, latest price 11.07, -3.82% change) and Tigermed (8.52% weight, latest price 65.65, +3.06% change) [1] Group 2: Market Capitalization - The total market capitalization of Aier Eye Hospital is approximately 103.232 billion yuan, while Tigermed's market capitalization is around 56.526 billion yuan [1] - Other notable companies include Mindray Medical (229.746 billion yuan) and Kanglong Chemical (55.486 billion yuan) [1] Group 3: Capital Flow - The net outflow of main funds from the ChiNext Medical Index constituents totaled 604 million yuan, while retail investors saw a net inflow of 412 million yuan [1] - The detailed capital flow shows that Tigermed had a net inflow of 14.716 million yuan from main funds, while retail investors experienced a net outflow of 1.41 million yuan [2]

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 日前，深圳华大基因股份有限公司发布公告 ， 宣布已完成法定代表人 、 总 经 理 的 工 商 变 更 登记 。 公司于2026年1月27日召开第四届董事会第八次会议 ， 审议通过了 《 关于聘任公司总经理 暨变更法定代表人的议案 》 ， 聘任 侯勇先生担任公司总经理 ， 同 时 担 任 公 司 法 定 代 表 人 ， 任期自公司第四届董事会第八次会议审议通过之日起至第四届董事会任期届满之日止 。 此前担任法定代表人 、 总经理的为赵立见 。 发 文 不 易 ， 请 帮 小 编 点 下 "❤️" ↓ | 转 载 ： 须 本 号 授 权 ， 请 联 系 主 编 | 来 源 ： 仪 器 信 息 网 | 责 编 ： 安 安 | 视 觉 ： 长 艳 柱 子 | 版 权 ： 本 文 部 分 素 材 源 自 网 络 ， 版 权 归 原 作 者 所 有 ， 观 点 代 表 作 者 本 人 ， 不 代 表 本 号 立 场 ...

Core Insights - Sequoia China, known for investing in innovative drugs and cutting-edge biotech, has made a surprising acquisition of the classic antibiotic Moxifloxacin (Avelox) from Bayer, establishing a new biopharmaceutical platform, Hangzhou Sanzhe Biopharmaceutical Co., Ltd. [1][2] - The acquisition is seen as a strategic move to leverage Moxifloxacin's existing market presence and cash flow while also aiming to introduce innovative products into the pipeline [5][8] Group 1: Acquisition Details - The acquisition involves Moxifloxacin, which has treated over 240 million patients globally, and includes key assets such as drug registration certificates and intellectual property [1][3] - Moxifloxacin was once a blockbuster drug for Bayer, generating nearly $1.2 billion in global sales in 2012, but has seen a decline in sales due to patent expiration and increased competition from generics [3][4] - In China, Bayer's market share for Moxifloxacin was approximately 34.75% in 2022, with local competitors capturing over 25% of the market [3] Group 2: Strategic Implications - Sequoia's acquisition reflects a shift from traditional VC investment strategies to a more private equity (PE) approach, focusing on optimizing and integrating mature businesses for stable cash flow [5][6] - The transaction is estimated to be between €160 million and €260 million, supported by financing from Shanghai Pudong Development Bank, indicating a leveraged buyout strategy [6][7] - The new platform, Sanzhe Biopharmaceutical, aims to operate Moxifloxacin as a "cash cow" while also serving as a foundation for introducing innovative products [7][8] Group 3: Leadership and Execution - Jin Xiaodong, a seasoned executive with extensive experience in multinational pharmaceutical companies, has been appointed to lead Sanzhe Biopharmaceutical, aligning with the company's dual strategy of managing mature products and seeking innovative assets [10][12] - Jin's background in commercializing mature products and his experience in strategic partnerships are seen as critical for the success of the new platform [11][12] Group 4: Challenges Ahead - Reviving Moxifloxacin in a competitive market, particularly under China's centralized procurement policies, presents a significant challenge for Sanzhe Biopharmaceutical [15] - The search for high-quality late-stage innovative assets is crucial, as the success of the strategy hinges on acquiring promising candidates in a competitive landscape [15][16] - Building an effective team and integrating the acquired global business with the new company's strategic goals will be essential for long-term success [16]